Clinical Trials Logo

Pigmented Villonodular Synovitis clinical trials

View clinical trials related to Pigmented Villonodular Synovitis.

Filter by:

NCT ID: NCT01643850 Completed - Clinical trials for Pigmented Villonodular Synovitis

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Start date: April 23, 2012
Phase: Phase 2
Study type: Interventional

This study, designed as a proof of concept study of MCS110 in pigmented villonodular synovitis, assessed the clinical response to MCS110 treatment in Pigmented Villonodular Synovitis (PVNS) patients, after a single or multiple intravenous doses of MCS110, using magnetic resonance imaging to assess tumor volume, and evaluated the pharmacokinetics/pharmacodynamics, safety and tolerability in this population.

NCT ID: NCT01261429 Completed - Clinical trials for Pigmented Villonodular Synovitis

Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

Start date: December 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy of nilotinib as a treatment of patients with progressive or relapsing pigmented villo-nodular synovitis / tenosynovial giant cell tumour (PVNS/TGCT) who cannot be treated by surgery. The primary objective of the study will be to determine the efficacy of 12 weeks (3 months) of nilotinib treatment as measured by the non progression rate (Complete response + Partial Response + Stable disease according to Response Evaluation Criteria In Solid Tumours - RECIST version 1.1) in patients with progressive or relapsing PVNS/TGCT who cannot be treated by surgery. this study is an international, multicentre, non-randomized, open-label phase II clinical trial with a Bayesian design. A maximum sample size of 50 patients will be included in the study

NCT ID: NCT01207492 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Start date: September 2010
Phase: Phase 2
Study type: Interventional

Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.